Amgen Inc. buy melinda
Start price
24.03.18
/
50%
€155.86
Target price
04.06.18
€166.87
Performance (%)
8.04%
End price
04.06.18
€167.19
Summary
This prediction ended on 04.06.18 with a price of €167.19. With a performance of 8.04%, the BUY prediction by melinda for Amgen Inc. closed with a slight gain. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | -0.338% | -0.338% | 11.814% | 14.277% |
| iShares Core DAX® | 0.794% | 2.841% | 22.630% | 72.985% |
| iShares Nasdaq 100 | 0.016% | -0.939% | 6.943% | 115.777% |
| iShares Nikkei 225® | 0.309% | -0.648% | 13.619% | 49.561% |
| iShares S&P 500 | 0.181% | -0.442% | 4.692% | 69.577% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
SectorDrug Pharmaceuticals Agenda 24/04 Veröffentlichung der Ergebnisse
Amgen erhält positive CHMP-Stellungnahme Anerkennung von Repatha® (Evolocumab) verhindert Herzinfarkt und Schlaganfall Gepostet um 07:44 EST
Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine positive Stellungnahme angenommen hat, um eine neue Indikation in Repatha® aufzunehmen